TB Archives – Page 36 of 50 – Treatment Action Group

TAG Applauds $12 Billion Replenishment of Global Fund to Fight AIDS, Tuberculosis and Malaria

December 3, 2013
Chad Cipiti

Treatment Action Group applauds the donors who have helped make it possible to save more lives by raising a record-breaking $12 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years. TAG also commends the Obama administration for its generous match of one dollar for every two dollars contributed by other donors, which helped to drive up funding commitments in the current replenishment round.

Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing

November 22, 2013
Chad Cipiti

Treatment Action Group (TAG) congratulates the Committee for Medicinal Products for Human Use (CHMP) for its recommendation to the European Medicines Agency (EMA) to grant marketing approval to delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) now in phase III clinical trials. MDR-TB treatment options that do not include new drugs are long, toxic, difficult to tolerate, and often ineffective.

2013 Symposium: Cascades – Improving TB Care

November 19, 2013
Chad Cipiti

The Treatment Action Group (TAG) “Cascades: Improving TB Care” symposium was held on November 1 at the 2013 International Union World Conference on Lung Health in Paris, France. Cosponsored by TAG, Médecins Sans Frontières (MSF), Partners In Health (PIH), the…

Tuberculosis Behind the Numbers Video Series

November 1, 2013
Chad Cipiti

Mike Frick of Treatment Action Group (TAG) and Audrey Zhang of Harvard College argue that patient-centered approaches in treatment for drug-resistant and drug-sensitive tuberculosis are needed. View Webinar Lindsay McKenna and Colleen Daniels of Treatment Action Group (TAG) describe the…

New Approaches to Drug-Resistant Tuberculosis

October 30, 2013
Chad Cipiti

A Double Blow: Private-Sector Funding for TB Research Drops Sharply Amid Severe Public-Sector Budget Cuts

October 29, 2013
Chad Cipiti

The 2013 Report on Tuberculosis Research Funding Trends, 2005–2012 finds that funding for tuberculosis research and development (TB R&D) dropped by US$30.4 million compared with 2011—the first time funding has fallen since TAG began tracking investments in 2005. Funding declined for diagnostic, drug, vaccine, and operational research, increasing the likelihood that new tools to fight TB will remain out of reach for the 8.7 million people who develop TB each year.

2013 Report on TB Research Funding Trends

October 25, 2013
Chad Cipiti

2013 Report on Tuberculosis Research Funding Trends, 2005–2012 NOVEMBER 2013 BY Mike Frick and Eleonora Jiménez-Levi Edited by Mark Harrington From the Executive Summary Over the last eight years, Treatment Action Group (TAG) has tracked annual spending on tuberculosis research…

An Obligatory Overhaul to Address Domestic TB Drug Shortages

October 4, 2013
Chad Cipiti

Bold strategies are required to remedy frequent stock-outs and supply interruptions By Lindsay McKenna Drug shortages, especially of tuberculosis (TB) drugs, have become increasingly common in the United States. Over the past year alone, the U.S. Centers for Disease Control…

U.S. TB Control: From Confidence to Crisis

October 4, 2013
Chad Cipiti

Funding cuts and shifting budgetary priorities threaten tuberculosis gains By Coco Jervis The United States is losing ground in its fight against the tuberculosis (TB) epidemic within its own borders. Sequestration and shifting priorities of Congress and the Obama administration…

TAGline Fall 2013

October 4, 2013
Chad Cipiti

The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.